PHARM Pharming Group NV
Listings ·
Pharming's subsidiary now controls 92.70 percent of Abliva through its SEK 0.45 cash offer, and it has extended the acceptance period to March 6, 2025 for holders who have not yet tendered. Pharming plans a compulsory acquisition of the rest and a delisting from Nasdaq Stockholm.
We have not published a story on Pharming Group NV yet. When there is news, it will appear here.
Pharming Group NV is a global biotechnology company that develops and commercializes therapies for rare and ultra-rare diseases, focused on immunological and genetic conditions. It currently commercializes two approved therapies. RUCONEST is a recombinant C1 esterase inhibitor protein replacement therapy for acute hereditary angioedema (HAE) attacks in adult and adolescent patients, approved in the European Economic Area and the United Kingdom in 2010 and in the United States in 2014, with the US as its commercial focus. Joenja (leniolisib) is an oral PI3K delta inhibitor for activated phosphoinositide 3-kinase delta syndrome (APDS), approved in the United States, United Kingdom, Australia and Israel, and in Japan for patients aged 4 years and older. The pipeline includes leniolisib in two Phase II studies for primary immunodeficiencies with immune dysregulation. Through its 2025 acquisition of Abliva AB, the company gained KL1333, now named napazimone, a potential first-in-disease therapy for mtDNA-driven primary mitochondrial disease. Napazimone is in a pivotal trial and passed a futility analysis on its two primary endpoints. For HAE, the text says the US is the core commercial opportunity and cites a diagnosed population of 2.67 per 100,000 in recent real-world US claims analyses.
| Product or program | What it is | Stage |
|---|---|---|
| RUCONEST (rhC1-INH) | Recombinant C1 esterase inhibitor for acute hereditary angioedema attacks | approved in the EEA, UK and US |
| Joenja (leniolisib) | Oral PI3K delta inhibitor for activated phosphoinositide 3-kinase delta syndrome | approved in the US, UK, Australia, Israel and Japan |
| Leniolisib for immune dysregulation | Treatment for primary immunodeficiencies with immune dysregulation | Phase II |
| Napazimone (KL1333) | Potential first-in-disease therapy for mtDNA-driven primary mitochondrial disease | pivotal clinical trial |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $376.1 million | $297.2 million |
| Research and development | $100.4 million | $83.1 million |
| Net income (loss) | $2.5 million | -$11.8 million |
| Cash from operations | $54.7 million | -$1.8 million |
| Cash and equivalents | $145.3 million | $54.9 million |
Our latest story on this, dated Feb 20, 2025: "Pharming lifts its stake in Abliva to 92.70 percent and extends cash offer to March 6". The story links the filing or release it is based on. Read the story.
Pharming Group NV trades under the ticker PHARM on EURONEXT.
Pharming Group NV is listed on EURONEXT. Our directory also records these other listings: DUS:PHGN; FWB:PHGN; GETTEX:PHGN; HAM:PHGN; HAN:PHGN; LS:A1H65A; LSIN:0QCO; LSX:A1H65A; MUN:PHGN; NASDAQ:PHAR; OTC:PHGUF; SWB:PHGN; TRADEGATE:PHGN; XETR:PHGN.
The SEC Central Index Key (CIK) for Pharming Group NV is 1828316. Its filings are on SEC EDGAR.
701,680,440 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-02.
Our directory records Pharming Group NV under Netherlands.
Our directory classifies Pharming Group NV as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Pharming Group NV is NL0010391025.
aibio.space lists Pharming Group NV among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as P7.
Pharming Group NV is a global biotechnology company that develops and commercializes therapies for rare and ultra-rare diseases, focused on immunological and genetic conditions. It currently commercializes two approved therapies.
RUCONEST (rhC1-INH): Recombinant C1 esterase inhibitor for acute hereditary angioedema attacks Stage: approved in the EEA, UK and US.
Joenja (leniolisib): Oral PI3K delta inhibitor for activated phosphoinositide 3-kinase delta syndrome Stage: approved in the US, UK, Australia, Israel and Japan.
$376.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Pharming Group NV reported net income of $2.5 million for the fiscal year ended Dec 31, 2025, and generated $54.7 million of cash from operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio